NewcelX Ltd. (NasdaqCM: NCEL)
Health Care · Biotechnology · CH
$3.65
+11.87% today · -55.2% 1Y
NewcelX Ltd. (NasdaqCM: NCEL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.57M and employs 11 people.
Over the last twelve months the share price has lost 55.2%, trading between 1.83 and 7.64.
Tweenvest scores NewcelX Ltd. across four factors: quality 36/100. Its strongest factor is quality.
NCEL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.57M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.16
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $7.64
- 52-week low
- $1.83
- Avg volume (3M)
- —
- Shares outstanding
- 5.38M
- Employees
- 11
- Next earnings
- —
About NewcelX Ltd.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
- ISIN
- CH1442297896
- Founded
- 2008
- Listed since
- Oct 24, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.